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Objectives This study examined the degree to which hospital performance for acute myocardial infarction (AMI) and heart
failure (HF) care processes are correlated.
Background Although AMI and HF care processes may be amenable to similar quality improvement interventions, whether
these are indeed correlated and whether hospitals with consistently superior performance for both care metrics
have the best outcomes remains unknown.
Methods We compared hospital performance of the Centers for Medicare & Medicaid Services AMI and HF core measures
in 283 hospitals submitting 10 or more patients to the Get With The Guidelines AMI and HF programs between
January 2005 and April 2009.
Results Median hospital adherence to AMI and HF composite measures were 93% (interquartile range: 87% to 97%) and
92% (interquartile range: 85% to 96%), respectively, with only a modest correlation between hospital perfor-
mance on these 2 composite metrics (r  0.50; 95% confidence interval: 0.41 to 0.58). Hospitals with superior
performance to both AMI and HF processes had significantly longer duration of Get With The Guidelines partici-
pation and lower adjusted in-hospital mortality (odds ratio: 0.79; 95% confidence interval: 0.63 to 0.99) for AMI
and HF patients, whereas hospitals with superior adherence to either alone had similar mortality rates as hospi-
tals with superior adherence to neither measure.
Conclusions Hospitals that had consistent, superior performance for both AMI and HF care had significantly lower risk-
adjusted mortality than those with superior performance either alone or for neither measure. Whether a single
scoring system to assess global, rather than condition-specific, quality of cardiovascular care would facilitate
care quality improvement more consistently and would optimize patient outcomes merits further
investigation. (J Am Coll Cardiol 2011;58:637–44) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.05.012Despite recent advances, acute myocardial infarction (AMI)
and heart failure (HF) remain associated with significant
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rized into national guidelines and
performance standards. These
outcomes are targets of hospital
quality improvement initiatives
(e.g., the American Heart Associ-
ation’s Get With The Guidelines
[GWTG] program) and are used
by accreditation agencies (e.g.,
Joint Commission) and payers
(e.g., Centers for Medicaid &
Medicare Services [CMS]) to as-
sess hospital quality of care (1,2).
Nevertheless, there are limited
data on how well AMI and HF process performances are
associated with one another. Specifically, do hospitals that
perform well on AMI metrics also perform well on HF
metrics? Because many of these care processes are amenable
to similar hospital quality improvement interventions, one
would expect their performance to be correlated strongly,
yet the interaction between these care processes has not
been characterized previously. Additionally, studies linking
care process performance with outcomes have been limited.
Although a few prior studies have found that hospitals with
superior adherence to AMI guideline recommendations and
performance measures have modestly lower risk-adjusted
in-hospital mortality rates (3,4), results from HF studies
have been more mixed (5–8).
For purposes of this study, we examined hospitals partic-
ipating in the GWTG program with the following objec-
tives: (1) to assess whether hospital-level performance of
AMI and HF performance were associated with each other,
(2) to describe the patient and hospital features of those
centers that provided consistently superior AMI and HF
process performance, and (3) to evaluate whether centers
with consistently superior process performance also have
superior AMI and HF patient outcomes.
Methods
Data source. The GWTG program is a large national,
observational registry started in 2000 to support and facilitate
quality improvement in the care of patients with cardiovascular
disease. Details of GWTG have been described previously
(9,10). In brief, the GWTG-coronary artery disease (CAD)
program enrolls patients hospitalized with a confirmed diag-
nosis of CAD (International Classification of Diseases-Ninth
Edition codes 410 through 414), whereas the GWTG-HF
program enrolls patients with a confirmed diagnosis of HF
(International Classification of Diseases-Ninth Edition code
428). Participation in GWTG is voluntary, but sites use the
data to support their performance reporting into the Joint
Commission and CMS. As such, GWTG hospitals adhere to
the CMS standard for core measure reporting, including
submission of consecutive eligible patients, to each database.
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CAD  coronary artery
disease
CMS  Centers for
Medicare & Medicaid
Services
GWTG  Get With The
Guidelines
HF  heart failureHowever, CMS does allow hospitals with more than 75admissions per quarter to use random sampling; thus, there are
a few large centers that choose to report a random selection of
cases on a quarterly basis. A prior study evaluating the
representativeness of the Organized Program to Initiate Life-
saving Treatment in Hospitalized Patients with Heart Failure
registry, which is the precursor to the GWTG-HF program
that was renamed after sponsorship change, but had largely
overlapping hospitals, compared registry patients to all other
fee-for-service Medicare beneficiaries that were hospitalized
nationwide for HF in the same time frame and found similar
patient characteristics and in-hospital outcomes without evi-
dence of selection bias (11).
Trained data abstractors at participating GWTG hospi-
tals collect detailed information on baseline demographic
and clinical characteristics, in-hospital care processes and
outcomes, and discharge treatment using a standardized set
of data elements and definitions. All GWTG study person-
nel were provided with training, overseen and audited by
American Heart Association GWTG program personnel,
on case ascertainment, data standards, and quality control.
Data are collected via a web-based patient management tool
that provides decision support with real-time online reporting
features. Using this data entry system, data quality is monitored
to assure completeness and accuracy of the submitted data.
Predefined logic criteria are used to identify any potential
double patient entry, in which case the participating site is
queried for verification or removal of redundant data. The data
abstraction tool also supports accurate data collection by
integrating logic features (e.g., edit and range checks) and user
alerts to identify potentially invalid format or values entry.
Required fields are structured so that valid data must be
entered before the data can be saved as a complete record and
entered into the database. Sites also receive individual data
quality reports each quarter to promote data completeness and
accuracy. Only sites and variables with a high degree of
completeness were used in analyses. Data auditing for a
random 5% sample of Organized Program to Initiate Lifesav-
ing Treatment in Hospitalized Patients with Heart Failure
(which had similar variables and coding instructions) showed
95% or more concordance in more than 90% of data fields
when compared with source documentation.
Because collected data are used primarily for institutional
quality improvement and because de-identified patient in-
formation is collected anonymously through retrospective
chart review, individual informed consent is not required
under the common rule. However, participation in GWTG
requires compliance with local regulatory and privacy guide-
lines and the approval of the institutional review board of
each hospital. For this study, the Duke Clinical Research
Institute served as the data analysis center and analyzed
aggregate de-identified data for research purposes.
Study population. From January 1, 2005, through April 1,
2009, 301 hospitals in GWTG submitted data to both the
CAD and HF programs, totaling 400,574 patients treated
for AMI or HF. We restricted this analysis to GWTG
hospitals that submitted at least 10 CAD and 10 HF patient
639JACC Vol. 58, No. 6, 2011 Wang et al.
August 2, 2011:637–44 Importance of Consistent AMI and HF Carerecords to define a threshold for stable hospital-level per-
formance assessment of each set of measures (18 hospitals;
7,351 patients excluded). This yielded a final population of
283 hospitals that varied in size, teaching status, and
surgical capability from all census regions of the United
States. A total of 393,223 patients (205,656 patients hos-
pitalized for AMI and 194,989 hospitalized for HF) were
treated at these hospitals and included in the assessment of
quality measure performance.
Quality measures. We evaluated hospital-level perfor-
mance of core quality measures for AMI and HF with
numerators and denominators for each measure as defined
by Joint Commission and CMS (12); these measures are
outlined in the Appendix. Composite process measure
performance for each hospital was calculated as the number
of times the selected care process was provided to eligible
patients divided by the total number of eligible patients (i.e.,
absence of contraindications). Patients who died during the
hospitalization (n  14,204) or were transferred to another
institution for inpatient care (n  16,917) were excluded
from the discharge process performance assessment.
Statistical methods. Descriptive statistics were used to
characterize hospital-level performance of AMI and HF
core measures. The correlation between hospital perfor-
mance in AMI measures and hospital performance in HF
measures was determined using Spearman correlation coef-
ficients. Superior adherence was defined as the upper tertile
of performance for each set of metrics. Hospitals then were
stratified into 4 groups: 1) superior adherence to both sets of
metrics; 2) superior adherence to AMI measures alone; 3)
superior adherence to HF measures alone; and 4) superior
adherence to neither measure. Hospital and patient charac-
teristics were compared across these groups, with median
(interquartile range) values and frequencies being reported
for continuous and categorical variables, respectively. Com-
parisons between groups were assessed with Pearson chi-
square tests for all categorical variables and Kruskal-Wallis
tests for all continuous or ordinal variables.
Multivariate logistic regression analysis using the gener-
alized estimating equation approach (13) was performed to
compare adjusted mortality for each group and was referenced
to the group of hospitals with superior adherence to neither
AMI nor HF core measures. This method accounted for
within-hospital correlation of responses (i.e., patients at the
same hospital were more likely to have similar responses
relative to patients in other hospitals). Variables for adjustment
included patient characteristics adapted from a previously
developed mortality risk model in this data set (14) (i.e., age,
sex, race, insurance status, body mass index, prior myocardial
infarction, prior CAD, prior HF, prior stroke or transient
ischemic attack, peripheral vascular disease, atrial fibrillation or
flutter, diabetes, hyperlipidemia, hypertension, chronic lung
disease, renal insufficiency, chronic dialysis, anemia, tobacco
use, depression, and systolic blood pressure at admission) and
hospital characteristics (i.e., bed size, teaching hospital, region,
surgical capability, and transplant capability). The c-statistic forthis model was 0.74 in the overall population, 0.77 among
AMI patients, and 0.69 among HF patients. As a secondary
approach, we created a propensity model with scores repre-
senting the estimated probability of a patient being treated at a
hospital with good adherence to both core measure sets
compared with a hospital with good adherence to neither
measure using the above patient and hospital variables. Inverse
probability-weighted modeling was performed to compare
risk-adjusted mortality outcomes between these 2 groups. The
results of this analysis were similar to those using the general-
ized estimating equation logistic regression approach.
Variables incorporated into the models were missing in less
than 7% patients, except for body mass index, which was
missing in 11% of patients and thus was imputed to gender-
specific median values. Patients who were transferred to an-
other institution for inpatient care (n 16,917) were excluded
from the denominator of mortality assessment because out-
comes after transfer cannot be determined because of U.S.
privacy laws. A 2-sided p value of  0.05 was considered
statistically significant for all tests. No adjustments were made
for multiple comparisons. All analyses were performed using
SAS software version 9.2 (SAS Institute, Cary, North Carolina).
Results
Among 283 hospitals participating in both GWTG-CAD
and GWTG-HF programs, median hospital performance
of the composite AMI core measures was 93.2%, with an
interquartile range of 87.4% to 96.5% (Fig. 1). Hospital
adherence to composite HF core measures was slightly
lower, with a median of 92.1% and an interquartile range of
85.3% to 96.0%. When hospitals are divided into tertiles
based on their performance of each set of core measures,
there were significant differences in the performance be-
tween the highest, middle, and lowest tertiles (Table 1).
Figure 1
Distribution of Acute Myocardial Infarction and
Heart Failure Core Measure Performance Across
Hospitals in the Get With The Guidelines Registry
The red bars represent heart failure (HF) performance and the
blue bars represent acute myocardial infarction (AMI) performance.
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correlation between hospital performance on one set of metrics
versus its performance in the other (r  0.50; 95% confidence
interval: 0.41 to 0.58). With superior adherence defined as the
upper tertile of performance for each set of metrics, hospitals
with superior adherence to AMI core measures performed
better with AMI than with HF core measures (97.2% vs.
92.8%; p  0.001). Similarly, hospitals with superior adher-
ence to HF core measures performed better with HF than with
AMI core measures (97.2% vs. 94.6%; p  0.001). When
hospitals were divided into 4 groups based on performance, 50
hospitals (18%) had superior adherence to both AMI and HF
core measures, 145 hospitals (51%) had superior adherence to
neither measure. The remaining hospitals were split evenly
between the 44 (16%) hospitals with superior adherence to AMI
measures only and the 44 (16%) hospitals with superior adherence
to HF measures only.
Table 2 shows that hospitals with superior adherence to
both AMI and HF measures were larger and were more
likely to be teaching hospitals compared with those that had
superior adherence to neither measure. Hospitals with
superior adherence to both AMI and HF measures were
likely to have participated longer in the GWTG program
than hospitals with superior adherence to neither measure.
Hospitals with superior adherence to both AMI and HF
measures treated patients who more frequently were
younger, male, and white compared with hospitals without
superior adherence to either. Only small differences were
seen in other patient characteristics (such as presence of
comorbid conditions) between groups.
Table 3 shows the performance of composite and indi-
vidual care measures in each group. For the composite AMI
measure, hospitals with superior adherence to both AMI
and HF core measures had better performance than hospi-
tals with superior adherence to AMI measures alone (p 
0.001). Nevertheless, reperfusion process performance was
best among hospitals with superior adherence to AMI only
(p  0.006 for fibrinolysis; p  0.0001 for primary
ercutaneous coronary intervention compared with the
ther 3 groups). For the composite HF measure, again
ospitals with superior adherence to both AMI and HF core
easures had better performance than hospitals with supe-
ior adherence to HF measures alone (p 0.015). Hospitals
Hospital Composite Adherence toF and AMI Core Measures Stratifiedby Terti es of Hospital P formance
Table 1
H spital Comp si e Adherence to
HF and AMI Core Measures Stratified
by Tertiles of Hospital Performance
Highest Tertile Middle Tertile Lowest Tertile
Median composite HF
adherence (IQR)
97.2 (96.0–98.7) 92.1 (90.2–93.8) 80.9 (72.7–85.3)
Median composite AMI
adherence (IQR)
97.2 (96.5–98.3) 93.2 (91.6–94.4) 84.0 (78.74–87.4)
p  0.0001 for all comparisons of highest versus middle tertile or for highest versus lowest tertile
or each set of core measures.
AMI  acute myocardial infarction; HF  heart failure; IQR  interquartile range.ith superior adherence to AMI measures only performedost HF measures well, except for providing HF discharge
nstructions (p  0.0001 compared with hospitals with good
dherence to HF or both); however, hospitals with superior
dherence to HF measures lagged only on almost all measures
f AMI care (p  0.001 for all measures compared with
hospitals with good adherence to AMI or both), except
smoking cessation counseling. Interestingly, although dis-
charge beta-blocker and angiotensin-converting enzyme inhib-
itor/angiotensin receptor blocker use are common to both sets
of performance measures, hospitals with superior adherence to
HF measures alone did not perform as well on these measures for
their AMI patients (p 0.0001 for both measures compared with
hospitals with good adherence to AMI or both).
Observed in-hospital mortality rates were lower in hospitals
with superior adherence to both AMI and HF measures
compared with hospitals with superior adherence to neither
measure (3.3 vs. 4.2%; p  0.0001). After adjustment for
patient and hospital characteristics, overall patient mortality
remained significantly lower in hospitals with superior adher-
ence to both (odds ratio: 0.79; 95% confidence interval: 0.63 to
0.99) compared with superior adherence to neither measure.
For AMI and HF patients individually, hospitals with superior
adherence to both also had the lowest mortality rates (Fig. 3)
and trended toward lower adjusted mortality, although this did
not reach statistical significance. In contrast, superior adherence
to only one set of metrics alone (either AMI or HF) was not
associated with improved mortality.
Discussion
The GWTG program provided a unique opportunity to
examine a broad range of hospitals providing cardiovascular
Figure 2 Correlation Between Hospital Performance of
Acute Myocardial Infarction and HF Core Measures
Each data point represents a single hospital. CI  confidence interval; HF 
heart failure.
gram; M
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that performed well in one set of cardiovascular metrics
(e.g., AMI care) do not necessarily do well in another set of
metrics (e.g., HF care). Yet the centers that excel at both
sets of metrics generally perform better than the centers that
excel at each alone. Furthermore, these hospitals have lower
risk-adjusted mortality for cardiovascular disease patients
compared with other hospitals.
Our results showed that hospitals participating in
GWTG generally performed well on the AMI and HF core
measures (median adherence: 93% and 92%, respectively),
which reflects the success of guideline dissemination and
quality improvement initiatives to date. Because many of the
AMI and HF care processes are amenable to similar quality
improvement interventions, one might expect a spillover
effect in which strong performance in one disease state
should also lead to superior performance in a separate, albeit
related, cardiovascular disease state. Despite this expecta-
tion, our study found only very modest correlation between
hospital performance of AMI and HF core measures (r 
Hospital Characteristics Stratified by Adherence to HF and AMI CoTable 2 Hospital Characteristics Stratified by Adherence to HF
Both (n  50) AMI Onl
Hospital characteristics
No. of beds 317 (191–587) 326 (20
Teaching hospital 51.2 5
Surgical facility 79.5 7
Duration in GWTG, yrs 4.52 (2.74–5.09) 4.13 (3.
Patient characteristics
Age, yrs 69.0 (58.0–80.0) 71.0 (59
Female sex 40.4 4
Nonwhite race 27.8 2
No insurance 7.4
Prior CAD 34.5 3
Prior MI 19.0 2
Prior HF 32.3 2
Prior stroke 9.0 1
Peripheral vascular disease 8.4 1
Diabetes 27.2 3
Hypertension 69.0 7
Hyperlipidemia 47.4 5
Atrial fibrillation/flutter 16.6 1
BMI, kg/m2 28.0 (24.3–32.8) 28.1 (24
Renal insufficiency 15.1 1
Dialysis 2.9
Chronic lung disease 19.2 2
Anemia 7.4
Tobacco abuse 24.7 2
Depression 3.9
Admission systolic blood pressure, mm Hg 134.0 (117.0–154.0) 138.0 (11
Admission heart failure signs‡ 10.6 1
Length of stay, days 4 (2–7) 4 (2–
Values are median (interquartile range) or %. *Compares hospitals with superior adherence to bot
superior adherence with both, neither, AMI only, and HF only. ‡Heart failure signs include acut
hepatomegaly.
BMI  body mass index; CAD  coronary artery disease; GWTG  Get With The Guidelines pro0.50). A potential explanation for this surprise finding maybe that the types of efforts, resources, and personnel needed
to implement performance improvement vary with the
particular care process selected (15). For example, hospitals
that excelled at performing AMI core measures did not
excel at providing HF discharge instructions, whereas hos-
pitals that excelled at providing the HF measures did not
perform as well with providing reperfusion-related mea-
sures. Along the same lines, a previous analysis of the
GWTG program showed that hospitals that performed well
on cardiovascular measures did not necessarily do well on
CMS pneumonia or surgical infection composite perfor-
mances (16). These data emphasize that dedicated efforts
(e.g., trained personnel, specialized resources) are needed to
drive disease-specific care improvement.
A second major finding of this study was that hospitals
that excelled in both AMI and HF measures generally
performed better on these metrics than hospitals that had
superior adherence to neither measure or superior adherence
to one set of measures alone. In part, this may be mediated
by the longer participation in the GWTG program observed
easuresAMI Core Measures
erior Adherence to
p Value* p Value†44) HF Only (n  44) Neither (n  145)
) 242 (146–398) 195 (116–322) 0.001 0.001
45.2 35.8 0.074 0.192
58.1 44.8 0.001 0.001
8) 4.69 (3.89–5.13) 3.44 (1.89–4.79) 0.002 0.001
.0) 71.0 (58.0–81.0) 72.0 (60.0–82.0) 0.001 0.001
43.4 46.4 0.001 0.001
34.0 31.8 0.001 0.001
7.0 5.7 0.001 0.001
27.7 36.6 0.001 0.001
18.5 17.0 0.001 0.001
30.0 31.8 0.088 0.001
9.6 10.9 0.001 0.001
8.5 8.8 0.006 0.001
25.4 29.3 0.001 0.001
71.7 67.7 0.001 0.001
46.6 42.5 0.001 0.001
16.8 20.8 0.001 0.001
.7) 27.6 (23.8–32.4) 27.5 (23.7–32.3) 0.001 0.001
13.6 14.1 0.001 0.001
3.2 3.2 0.031 0.038
18.7 21.0 0.001 0.001
7.5 8.9 0.001 0.001
23.5 21.1 0.001 0.001
3.9 6.3 0.001 0.001
58.0) 137.0 (118.0–158.0) 138.0 (119.0–158.0) 0.001 0.001
15.8 11.0 0.001 0.001
4 (2–7) 4 (2–6) 0.001 0.001
nd HF core measures with hospitals with superior adherence to neither. †Compares all 4 groups:
onary edema, pulmonary congestion or volume overload, S3, rales, lower extremity edema, or
I  myocardial infarction; other abbreviations as in Table 1.re Mand
Sup
y (n 
3–499
0.0
5.0
04–4.9
.0–81
4.2
1.0
5.7
6.3
1.6
9.6
2.4
2.7
1.0
2.2
0.8
8.6
.4–32
2.0
3.2
2.3
9.6
6.4
9.0
9.0–1
2.7
6)
h AMI a
e pulmfor the hospitals who had superior adherence to both
tricular
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to neither measure. The GWTG program tracks and
regularly provides performance feedback on process of care
measures, quality improvement tools, and process redesign
support to improve care iteratively (17). Previous studies
have shown that hospitals enrolled in a quality improvement
initiative have better processes of care than nonparticipating
hospitals (18). As such, superior adherence to both AMI
and HF measures simply may be a marker of hospitals with
early interest and action in quality improvement.
Alternatively, superior adherence to both AMI and HF
measures may reflect more organized, synergistic hospital
care processes, rather than the additive effect of individual
AMI and HF care measures. An examination of the metrics
common to both sets of core measures helps to illustrate this
point. Although common to both AMI and HF core
measures, discharge beta-blockers are provided variably to
AMI and HF patients. Hospitals with superior adherence to
AMI measures do well with discharge beta-blocker use
for AMI patients, but do not perform this metric as well for
HF patients, whereas hospitals with superior adherence to
both AMI and HF measures perform this metric well for
both AMI and HF patients, and in fact do better on this
metric than hospitals that have good adherence to either
AMI or HF alone. These results extend earlier findings by
Eagle et al. (19) and Fonarow et al. (20), who discovered
that centers with disease-specific standardized care algo-
rithms, order sets, and discharge processes are more likely to
prescribe recommended treatments wherever indicated.
Most importantly, hospitals with superior performance
on both AMI and HF measures had lower risk-adjusted
mortality compared with hospitals adherent to neither or
Hospital Performance of AMI and HF Core MeasuresTable 3 Hospital Performance of AMI and HF Core Measures
Overall Both
No. of hospitals 283 50
No. of patients 393,223 86,492
AMI core measures
Admission aspirin 94.3 98.5
Discharge aspirin 95.1 98.6
Discharge ACEI/ARB in LVSD 89.4 94.9
Discharge beta-blocker 94.5 98.3
Smoking cessation counseling 96.1 98.3
Time to fibrinolysis 30 min 37.5 37.1
Door to balloon 90 min 58.9 63.6
Composite AMI performance 93.5 97.5
HF core measures
Discharge instructions 85.3 96.1
LVEF assessment 96.0 99.0
Discharge ACEI/ARB in LVSD 89.9 96.3
Discharge beta-blocker in LVSD 91.1 97.3
Smoking cessation counseling 94.4 98.7
Composite HF performance 91.2 97.5
ACEI  angiotensin-converting enzyme inhibitor; ARB angiotensin receptor blocker; LVEF  left veneither alone. Part of this improvement in patient outcomesmay be accounted for by the more consistent use of
therapies, although previous studies found variable associa-
tion between current performance measures and outcomes
(5,8). For AMI patients, Peterson et al. (3) reported an
association between guideline adherence and mortality (i.e.,
every 10% increase in hospital performance was associated
with a 10% decrease in in-hospital mortality). Similarly,
Bradley et al. (4) showed that AMI process measure
performance was associated with improved outcomes, yet
noted that only a small component (6%) of hospital-level
variation in mortality was explained by these care differ-
ences. For HF, the results were somewhat mixed. The
Hospital Quality Alliance program found that higher hos-
pital performance for both AMI and HF patients had
modestly improved outcomes (8,21). However, Fonarow et
al. (5) and Patterson et al. (7) found that the current
American College of Cardiology/American Heart Associa-
tion HF performance measures were not tightly associated
with mortality, although an emerging measure (use of
beta-blockers in patients with reduced left ventricular ejec-
tion fraction) was tightly associated (6).
A third explanation for the lower mortality in hospitals with
superior performance on both AMI and HF measures may be
a better global quality of care provided in contrast to hospitals
with superior adherence to neither, AMI alone, or HF alone.
Each set of performance measures captures information in a
select group of patients with a given condition and measures
discrete disease-related care processes. However, risk-adjusted
mortality and other outcomes are likely influenced by factors
that are not routinely assessed in a registry database, but are
closely associated with the overall quality of hospital care (22).
In a survey of high-performing and low-performing hospitals,
Superior Adherence to
p ValueAMI Only HF Only Neither
44 44 145
99,008 63,719 144,004
97.7 90.7 90.6 0.001
98.5 91.5 91.3 0.001
93.2 86.8 83.6 0.001
98.0 91.4 90.2 0.001
97.9 95.1 92.6 0.001
47.6 33.9 33.1 0.035
67.4 55.2 50.0 0.001
96.8 90.2 89.2 0.001
79.7 95.8 79.9 0.001
96.2 99.2 93.4 0.001
87.8 94.6 85.9 0.001
91.0 95.4 85.7 0.001
94.0 97.9 91.1 0.001
89.3 96.9 87.2 0.001
ejection fraction; LVSD left ventricular systolic dysfunction: other abbreviations as in Table 1.high performers had more consistent and committed leader-
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August 2, 2011:637–44 Importance of Consistent AMI and HF Careship infrastructure, greater investment in information technol-
ogy, and clearer mechanisms to ensure clinical accountability
(23). From this, we postulate that hospitals that are able to
provide superior adherence to both AMI and HF measures
reflect an optimal hospital culture—that is, resource allocation,
activity of quality oversight committees, staffing, or other
processes—that elevate the global quality of care and outcomes.
Our results should be interpreted in light of several
considerations. First, although the observational nature of
this study permits real-world assessment of care patterns,
the association between care processes and outcomes in this
observation study do not necessarily prove causality, and we
cannot eliminate the possibility of confounding from unmea-
sured variables explaining the difference in risk-adjusted mor-
tality. Second, GWTG currently only reports in-hospital
outcomes, so it will be important to assess the association of
process measure improvement with longitudinal outcomes.
Third, although GWTG represents a spectrum of hospital
types and sizes, participation is voluntary, reflecting an inherent
interest in quality improvement, and thus may not be repre-
Figure 3 Association of Hospital Adherence to AMI and HF Me
Graph showing adherence with (top) overall in-hospital mortality, (middle) in-hospital m
OR  odds ratio; other abbreviations as in Figures 1 and 2.sentative of national care patterns and outcomes.Our results have several important implications. First, it
cannot be assumed that hospitals that excel in one set of
cardiovascular metrics necessarily will perform well in another
set of cardiovascular metrics; thus, targeted performance feed-
back and improvement efforts are needed to elevate global
hospital quality of care (24). However, the implementation of
care processes in one particular therapeutic area should be
examined for potential synergism in nurturing more wide-
spread changes across quality indicators (25,26). Second, from
a hospital management perspective, quality improvement proj-
ects entail organization of both clinical (e.g., prescription of a
particular medication) and administrative (e.g., providing dis-
charge HF education or smoking cessation counseling) activ-
ities of care (27,28). Finally, the quality of a hospital’s care—
and by extrapolation, its patient outcomes—may be reflected
more accurately by its performance on a combined set of
cardiovascular disease measures than by a single set of perfor-
mance measures. Given the need to assess and improve global
quality of care, assessments of hospital performance may be
aligned better with the overall quality of inpatient cardiovas-
s
ty for AMI patients, and (bottom) in-hospital mortality for HF patients.asure
ortalicular care, rather than the delivery of care within a specific
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Importance of Consistent AMI and HF Care August 2, 2011:637–44therapeutic area. For example, if a pay-for-performance system
is used to incentivize improvement in cardiovascular outcomes,
rather than using traditional separate AMI and HF quality
measures, a single scoring system assessing clinical and admin-
istrative care activities for all cardiovascular disease patients
may better facilitate the identification of concrete quality
improvement targets and implementation of practice changes
more universally across multiple disease states, and ultimately
may improve overall patient outcomes (29).
Conclusions
Our study found only a modest correlation between a hospital’s
performance in AMI measures compared with its performance
in HF measures. However, centers that excel at both AMI and
HF measures have better performance than centers that excel
at neither or at each alone, and these centers have significantly
better patient outcomes. Further investigation and refining of
quality improvement strategies is needed to optimize the
consistency of hospital quality of cardiovascular care.
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APPENDIX
For the hospital core quality measures for AMI and HF,
please see the online version of this article.
